UBS AM
RYTM icon

UBS AM’s Rhythm Pharmaceuticals RYTM Stock Holding History

UBS AM’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.2M Sell
514,850
-26,600
-5% -$2.41M 0.01% 623
2026
Q1 		$47.1M Sell
541,450
-7,570
-1% -$736K 0.01% 637
2025
Q4 		$58.8M Buy
549,020
+111,548
+25% +$11.8M 0.01% 581
2025
Q3 		$44.2M Buy
437,472
+209,845
+92% +$19.5M 0.01% 625
2025
Q2 		$14.4M Buy
227,627
+101,845
+81% +$6.24M ﹤0.01% 1176
2025
Q1 		$6.66M Sell
125,782
-92,762
-42% -$5.15M ﹤0.01% 1417
2024
Q4 		$12.2M Sell
218,544
-6,829
-3% -$377K ﹤0.01% 1155
2024
Q3 		$11.8M Sell
225,373
-11,058
-5% -$530K ﹤0.01% 1149
2024
Q2 		$9.71M Buy
236,431
+29,451
+14% +$1.18M ﹤0.01% 1150
2024
Q1 		$8.97M Sell
206,980
-2,958
-1% -$129K ﹤0.01% 1044
2023
Q4 		$9.65M Sell
209,938
-127,326
-38% -$4.02M ﹤0.01% 996
2023
Q3 		$7.73M Buy
337,264
+131,229
+64% +$2.94M ﹤0.01% 1041
2023
Q2 		$3.68M Hold
206,035
– – ﹤0.01% 1372
2023
Q1 		$3.68M Buy
206,035
+163,838
+388% +$4.11M ﹤0.01% 1372
2022
Q4 		$1.23M Buy
42,197
+12,260
+41% +$315K ﹤0.01% 1754
2022
Q3 		$733K Sell
29,937
-24,886
-45% -$463K ﹤0.01% 2145
2022
Q2 		$228K Buy
54,823
+25,392
+86% +$139K ﹤0.01% 2553
2022
Q1 		$339K Hold
29,431
– – ﹤0.01% 2565
2021
Q4 		$294K Buy
29,431
+4,216
+17% +$47.4K ﹤0.01% 2682
2021
Q3 		$329K Hold
25,215
– – ﹤0.01% 2601
2021
Q2 		$494K Buy
25,215
+14,719
+140% +$306K ﹤0.01% 2543
2021
Q1 		$223K Sell
10,496
-18,630
-64% -$540K ﹤0.01% 2544
2020
Q4 		$866K Sell
29,126
-2,838
-9% -$72.1K ﹤0.01% 2062
2020
Q3 		$693K Buy
31,964
+12,901
+68% +$296K ﹤0.01% 1990
2020
Q2 		$425K Buy
+19,063
New +$372K ﹤0.01% 2183

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS AM's RYTM Position: Q2 2026 in Review

UBS AM reduced its Rhythm Pharmaceuticals (RYTM) stake by 4.9% in Q2 2026, selling an estimated $2.41M and leaving 514,850 shares worth $57.2M. The position accounts for 0.01% of the portfolio, ranked #623.

UBS AM first reported a position in RYTM in Q2 2020 and has held it in 25 quarters since. The position peaked at $58.8M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • UBS AM held 514,850 shares of Rhythm Pharmaceuticals worth $57.2M as of Q2 2026.
  • UBS AM sold 26,600 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.41M.
  • Rhythm Pharmaceuticals made up 0.01% of UBS AM's portfolio in Q2 2026, its #623 holding.
  • UBS AM first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • UBS AM's Rhythm Pharmaceuticals position peaked at $58.8M in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.